乳腺癌内分泌治疗进展
Advances in Endocrine Therapy for Breast Cancer
DOI: 10.12677/ACM.2023.1391925, PDF,   
作者: 迪力努尔·艾麦提, 马秀英：新疆医科大学第四临床医学院，新疆 乌鲁木齐；王 薇*：新疆医科大学附属中医医院普外二科，新疆 乌鲁木齐
关键词: 乳腺癌；内分泌治疗；抗雌激素类药物；AIs；促黄体生成素释放激素拮抗剂；Breast Cancer； Endocrine Therapy； Anti-Estrogenic Drugs； AIs； Luteinizing Hormone-Releasing Hormone Antagonists
摘要: 乳腺癌是一种常见的严重威胁女性健康的恶性肿瘤。内分泌治疗是激素受体阳乳腺癌患者的一线治疗方法，具有延长生存期、治疗方式简单、副作用较化疗小等特点，在乳腺癌治疗中占着重要的地位。随着内分泌治疗的广泛应用，内分泌治疗耐药成为临床上面临的重大问题，而内分泌治疗联合靶向治疗弥补了该缺点。本文就乳腺癌内分泌治疗的进展作综述。
Abstract: Breast cancer is a common malignant tumor that poses a serious threat to women’s health. For hormone receptor-positive breast cancer, endocrine therapy has become the main treatment for prolonging survival, simplicity of treatment and less side effects than chemotherapy, and plays an important role in breast cancer treatment. However, with the widespread use of endocrine therapy, the emergence of drug resistance has made endocrine therapy more difficult, and endocrine thera-py combined with targeted therapy to compensate for this drawback. This article reviews the pro-gress of endocrine therapy for breast cancer.
文章引用：迪力努尔·艾麦提, 马秀英, 王薇. 乳腺癌内分泌治疗进展[J]. 临床医学进展, 2023, 13(9): 13777-13783. https://doi.org/10.12677/ACM.2023.1391925

参考文献

[1] 赵鑫, 邓姗. 年轻未生育的早期乳腺癌患者内分泌治疗期间发生子宫内膜增生的管理策略探讨[J]. 生殖医学杂志, 2022, 31(5): 681-684.
[2] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[3] Soerjomataram, I. and Bray, F. (2021) Planning for Tomorrow: Global Cancer Incidence and the Role of Prevention 2020-2070. Nature Reviews Clinical Oncology, 18, 663-672. [Google Scholar] [CrossRef] [PubMed]
[4] 刘斌亮, 谢宁, 欧阳取长. 早期HR阳性/HER2阳性乳腺癌的治疗选择与思考[J]. 中国临床新医学, 2022, 15(6): 482-487.
[5] Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Evidence. Lancet, 394, 1159-1168. [Google Scholar] [CrossRef] 
[6] Lazzeroni, M., Puntoni, M., Guerrieri-Gonzaga, A., et al. (2023) Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Ne-oplasia: A 10-Year Follow-Up of TAM-01 Study. Journal of Clinical Oncology, 41, 3116-3121. [Google Scholar] [CrossRef] 
[7] Tjan-Heijnen, V.C.G., Lammers, S.W.M., Geurts, S.M.E., et al. (2023) Extended Adjuvant Aromatase Inhibition after Sequential Endocrine Therapy in Postmenopausal Women with Breast Cancer: Follow-Up Analysis of the Randomised Phase 3 DATA Trial. eClinicalMedicine, 58, Article ID: 101901. [Google Scholar] [CrossRef] [PubMed]
[8] 孙蓉. 内分泌干预治疗对于女性乳腺癌发生关联的荟萃分析[D]: [硕士学位论文]. 西宁: 青海大学, 2021.
[9] 郭宗儒. 以雌受体为靶标的骨质疏松治疗药雷洛昔芬[J]. 药学学报, 2021, 56(7): 2033-2038.
[10] 地里呼玛尔•吐鲁洪, 李欣芳. HR+/HER2−乳腺癌内分泌治疗的研究进展[J]. 东南国防医药, 2021, 23(4): 387-392.
[11] 黄汉生. 乳腺癌内分泌治疗进展[J]. 中国现代医生, 2020, 58(14): 178-181.
[12] 张杨梅, 周一舟, 王翔, 等. 内分泌治疗方法治疗乳腺癌的价值研究[J]. 中国保健营养, 2019, 29(19): 45.
[13] 吕丹, 吴云, 马飞. 2021年乳腺癌治疗新进展[J]. 肿瘤综合治疗电子杂志, 2022, 8(1): 85-93.
[14] De Placido, S., Gallo, C., De Laurentiis, M., et al. (2018) Adjuvant Anastrozole versus Exemestane versus Letrozole, Upfront or after 2 Years of Tamoxifen, in Endocrine-Sensitive Breast Cancer (FATA-GIM3): A Randomised, Phase 3 Trial. The Lancet Oncology, 19, 474-485. [Google Scholar] [CrossRef] 
[15] Del Mas-tro, L, Mansutti, M, Bisagni, G., et al. (2021) Extended Therapy with Letrozole as Adjuvant Treatment of Postmenopau-sal Patients with Early-Stage Breast Cancer: A Multicentre, Open-Label, Randomised, Phase 3 Trial. The Lancet Oncol-ogy, 22, 1458-1467. [Google Scholar] [CrossRef] 
[16] Cuzick, J., Sestak, I., Forbes, J.F., et al. (2020) Use of Anastrozole for Breast Cancer Prevention (IBIS-II): Long-Term Results of a Randomised Controlled Trial. Lancet, 395, 117-122. [Google Scholar] [CrossRef] 
[17] Gnant, M., Pfeiler, G., Steger, G.G., et al. (2019) Adjuvant Denosumab in Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer (ABCSG-18): Disease-Free Survival Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 339-351. [Google Scholar] [CrossRef] 
[18] 詹和道, 姚江凌, 崔红旺. 地诺单抗对比双膦酸盐类治疗骨质疏松有效性和安全性的Meta分析[J]. 中国药房, 2023, 34(11): 1384-1388.
[19] Johansson, A., Dar, H., van’t Veer, L.J., et al. (2022) Twenty-Year Benefit from Adjuvant Goserelin and Tamoxifen in Premenopausal Patients with Breast Cancer in a Controlled Randomized Clinical Trial. Journal of Clin-ical Oncology, 40, 4071-4082. [Google Scholar] [CrossRef] 
[20] Robertson, J.F.R., Bondarenko, I.M., Trishkina, E., et al. (2016) Fulvestrant 500 mg versus Anastrozole 1 mg for Hormone Receptor-Positive Advanced Breast Cancer (Falcon): An International, Randomised, Double-Blind, Phase 3 Trial. Lancet, 388, 2997-3005. [Google Scholar] [CrossRef] 
[21] Wang, J., Cai, L., Song, Y., et al. (2023) Clinical Efficacy of Fulvestrant Versus Exemestane as First-Line Therapies for Chinese Postmenopausal Oestrogen-Receptor Posi-tive/Human Epidermal Growth Factor Receptor 2 -Advanced Breast Cancer (FRIEND Study). European Journal of Cancer, 184, 73-82. [Google Scholar] [CrossRef] [PubMed]
[22] 阿迪莱•艾萨, 赵菁, 袁瑛. 乳腺癌内分泌治疗耐药机制的研究进展[J]. 解放军医学杂志, 2021, 46(7): 702-709.
[23] 夏雯, 王树森. 激素受体阳性乳腺癌靶向治疗进展[J]. 中国肿瘤临床, 2017, 44(13): 635-639.
[24] Brandão, M., Maurer, C., Ziegelmann, P.K., et al. (2020) Endocrine Therapy-Based Treatments in Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer: System-atic Review and Network Meta-Analysis. ESMO Open, 5, E000842. [Google Scholar] [CrossRef] [PubMed]
[25] Ditsch, N., Wöcke, A., Untch, M., et al. (2022) AGO Rec-ommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022. Breast Care, 17, 403-420. [Google Scholar] [CrossRef] [PubMed]
[26] 易宗毕. 《HR+/HER2−转移性乳腺癌患者内分泌治疗和靶向治疗: ASCO更新版指南》解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(4): 37-42.
[27] Sledge Jr., G.W., Toi, M., Neven, P., et al. (2020) The Effect of Abemaciclib plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncology, 6, 116-124. [Google Scholar] [CrossRef] [PubMed]
[28] Zhang, Q.Y., Sun, T., Yin, Y.M., et al. (2020) MONARCH plus: Abemaciclib plus Endocrine Therapy in Women with HR+/HER2− Advanced Breast Cancer: The Multinational Randomized Phase III Study. Therapeutic Advances in Medical Oncology, 12. [Google Scholar] [CrossRef] [PubMed]
[29] Johnston, S.R.D., Harbeck, N., Hegg, R., et al. (2020) Abema-ciclib Combined with Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of Clinical Oncology, 38, 3987-3998. [Google Scholar] [CrossRef] 
[30] Rugo, H.S., O’Shaughnessy, J., Boyle, F., et al. (2022) Adjuvant Abemaciclib Combined with Endocrine Therapy for High-Risk Early Breast Cancer: Safety and Patient-Reported Out-comes from the monarchE Study. Annals of Oncology, 33, 616-627. [Google Scholar] [CrossRef] [PubMed]
[31] Sledge Jr., G.W., Toi, M., Neven, P., et al. (2017) MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women with HR+/HER2− Advanced Breast Cancer Who Had Pro-gressed While Receiving Endocrine Therapy. Journal of Clinical Oncology, 35, 2875-2884. [Google Scholar] [CrossRef] 
[32] Rugo, H.S., Lerebours, F., Ciruelos, E., et al. (2021) Alpelisib plus Fulvestrant in PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer after a CDK4/6 Inhibitor (BY-Lieve): One Cohort of a Phase 2, Multicentre, Open-Label, Non-Comparative Study. The Lancet Oncology, 22, 489-498. [Google Scholar] [CrossRef] 
[33] Turner, N.C., Oliveira, M., Howell, S.J., et al. (2023) Capi-vasertib in Hormone Receptor-Positive Advanced Breast Cancer. The New England Journal of Medicine, 388, 2058-2070. [Google Scholar] [CrossRef] 
[34] Beaver, J.A. and Park, B.H. (2012) The BOLERO-2 Trial: The Ad-dition of Everolimus to Exemestane in the Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer. Future Oncology, 8, 651-657. [Google Scholar] [CrossRef] [PubMed]
[35] Shao, Z., Cai, L., Wang, S., et al. (2021) 238P BOLERO-5: A Phase II Study of Everolimus and Exemestane Combinati on in Chinese Post-Menopausal Women with ER+/HER2− Advanced Breast Cancer. Annals of Oncology, 32, S463. [Google Scholar] [CrossRef] 
[36] Connolly, R.M., Zhao, F., Miller, K.D., et al. (2021) E2112: Randomized Phase III Trial of Endocrine Therapy plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology, 39, 3171-3181. [Google Scholar] [CrossRef] 
[37] Jiang, Z., Li, W., Hu, X., et al. (2019) Tucidinostat plus Exemestane for Postmenopausal Patients with Advanced, Hormone Receptor-Positive Breast Cancer (ACE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 20, 806-815. [Google Scholar] [CrossRef] 
[38] Biello, F., Platini, F., D’Avanzo, F., et al. (2021) Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights. Biomolecules, 11, Article No. 125. [Google Scholar] [CrossRef] [PubMed]
[39] Schmid, P., Cortes, J., Joaquim, A., et al. (2023) XENERA-1: A Randomised Double-Blind Phase II Trial of Xentuzumab in Combination with Everolimus and Exemestane versus Everolimus and Exemestane in Patients with Hormone Receptor-Positive/her2-Negative Metastatic Breast Cancer and Non-Visceral Disease. Breast Cancer Research, 25, Article No. 67. [Google Scholar] [CrossRef] [PubMed]

为你推荐